cagrisema phase 3 results 2025 cagrilintide semaglutide combination obesity drug: what the data shows HCPLive - CagriSema, a fixed
HCPLive CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss to placebo in adults with obesity or overweight and T2D in the Phase Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025 How much weight can you lose with cagrisema?
Pay in 4 interest-free payments of $5.91 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21


